Evidence map›Paper›PMID 26374732›Full record

ArticleBritish journal of clinical pharmacology2016

Use of thiazolidinediones and the risk of elective hip or knee replacement: a population based case-control study.

Johannes T H Nielen, Frank de Vries, Pieter C Dagnelie, Bart J F van den Bemt, Pieter J Emans, Arief Lalmohamed, Anthonius de Boer, Annelies Boonen

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of clinical pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Type 2 diabetes mellitus and osteoarthritis.Seminars in arthritis and rheumatism · 2019
    Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Johannes T H NielenDepartment of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University, Utrecht.
Frank de VriesDepartment of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University, Utrecht.
Pieter C DagnelieDepartment of Epidemiology, CAPHRI School for Public Health and Primary Care, and CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht.
Bart J F van den BemtDepartment of Pharmacy, Sint Maartenskliniek, Nijmegen.
Pieter J EmansDepartment of Orthopaedics, Maastricht University Medical Center, Maastricht.
Arief LalmohamedDepartment of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University, Utrecht.
Anthonius de BoerDepartment of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University, Utrecht.
Annelies BoonenDepartment of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, the Netherlands.
Maastricht University · NLUtrecht University · NLPharmo Institute · NLRadboud University Nijmegen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsOsteoarthritis (OA) is the most common musculoskeletal condition in the elderly population. However, no disease modifying drug exists for this disease. In vivo animal studies have suggested that thiazolidinediones (TZD) may be used as disease modifying osteoarthritis drugs (DMOADs). To our knowledge, this has not yet been examined in humans before. The aim was to determine the risk of total joint replacement (TJR) in patients using TZDs compared with diabetic patients using other antidiabetic drugs.

methodsA population based case-control study was performed using the Clinical Practice Research Datalink (CPRD). Cases (n = 94 609) were defined as patients >18 years of age who had undergone total knee (TKR) or hip replacement (THR) between 2000 and 2012. Controls were matched by age, gender and practice/surgery. Conditional logistic regression analyses were used to estimate the risk of TKR and THR with the use of TZDs in patients currently using one or more antidiabetic drugs. In order to determine effect with prolonged use, we also stratified TZD users by total number of prescriptions prior to surgery. We statistically adjusted our analyses for lifestyle factory, comorbidities and concomitant drug use.

resultsThere was no difference in risk of TKR (OR 1.09, 95% CI 0.93, 1.27) and THR (OR 0.92, 95% CI 0.76, 1.10) when TZD users were compared with other AD users. Furthermore, we did not find an association with prolonged use of TZDs and TJR.

conclusionDespite promising results from animal in vivo studies, this study did not find any evidence for a disease modifying osteoarthritic effect of TZDs.

Indexed as

AgedArthroplasty, Replacement, HipArthroplasty, Replacement, KneeCase-Control StudiesDiabetes MellitusElective Surgical ProceduresFemaleHumansHypoglycemic AgentsLogistic ModelsMaleOsteoarthritis, HipOsteoarthritis, KneeThiazolidinedionesTreatment OutcomeHypoglycemic AgentsThiazolidinedionesarthroplastydiabetes mellitusglitazonesosteoarthritisthiazolidinediones

Identifiers

PMID26374732
PMCPMC4833153
OpenAlexW2108510796

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.